TrialBreast cancer research : BCR2019

A phase I/II study of epertinib plus trastuzumab with or without chemotherapy in patients with HER2-positive metastatic breast cancer.

Iain R Macpherson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.